BCHE and early-onset autosomal dominant Alzheimer disease: Figure 2 schematically shows some therapeutic strategies that over time have been investigated for the treatment of AD. Existing AD therapies focused on agents that aimed to increase the cerebral acetylcholine levels by facilitating cholinergic neurotransmission through inhibiting cholinesterase. These compounds, known as cholinesterase inhibitors, offer a viable target across key sign domains of Alzheimer’s disease [40,41,42,43].